NEUROMUSCULAR DISORDERS is a premier academic journal published by PERGAMON-ELSEVIER SCIENCE LTD, focusing on the latest research and developments in the fields of neurology, genetics, and pediatric health. With an ISSN of 0960-8966 and an E-ISSN of 1873-2364, this journal has established a significant presence since its inception in 1991, and it continues to contribute to the scientific community with its impactful findings and reviews. The journal boasts a commendable impact factor, reflected in its placement in the Q2 category for Clinical Genetics and Neurology, as well as its positioning in the top tier Q1 for Pediatrics, Perinatology and Child Health according to the latest quartile assessments. With Scopus rankings such as Rank #71/330 in Pediatrics and Rank #51/99 in Clinical Genetics, NEUROMUSCULAR DISORDERS is recognized for its contribution to advancing knowledge in neuromuscular diseases. The journal is essential for researchers, clinicians, and students interested in the intricate relationship between genetics and neurological disorders, providing valuable insights that drive innovation and improve patient care.

Discover Oncology, published by SPRINGER, is an influential journal based in Germany that focuses on the latest advancements in the fields of oncology and endocrinology. With an evolving scope that spans critical research from 2021 to 2024, this journal aims to provide a platform for innovative ideas and research findings that can significantly impact clinical practices. Although it currently holds a Q3 ranking in several Cancer Research and Endocrine category quartiles, its commitment to open access ensures that relevant knowledge is available to a wider audience, facilitating the exchange of ideas among researchers, professionals, and students. As evidenced by its growing presence in various medical spheres, including a Q2 ranking in Endocrinology and Diabetes, the journal plays a crucial role in advancing multidisciplinary research that integrates oncology with broader biological and medical parameters. For those in the field, Discover Oncology serves as both a resource and a community hub, encouraging collaboration and exploration of emerging findings that can lead to novel therapeutic approaches.

ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE is a distinguished journal that serves as a vital platform for disseminating innovative research and insightful reviews in the field of dermatology and venereology. Published by MASSON EDITEUR, this journal has been a cornerstone for professionals and researchers since its inception in 1977, offering a wealth of knowledge that spans decades. With its ISSN 0151-9638 and E-ISSN 2214-5451, it is indexed within leading databases, ensuring that the published work reaches a broad audience. The journal currently holds a Q3 ranking in the dermatology category, reflecting its commitment to quality and rigorous peer-review processes. While the journal is not open access, it provides an extensive archive of valuable studies that contribute to advancements in skin health and treatment methodologies. Located in Issy-les-Moulineaux, France, ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE continues to attract submissions from esteemed professionals, enhancing its reputation as a crucial resource for those dedicated to the ongoing development of dermatological sciences.

European Journal of Translational Myology is a premier, open access journal published by PAGEPRESS PUBL, dedicated to advancing research in the dynamic field of myology and its applications in various medical disciplines. Established in 2010, this journal disseminates crucial findings pertinent to translational myology, covering aspects within Cell Biology, Molecular Biology, Neurology, and Orthopedics and Sports Medicine. With a notable presence in the Scopus rankings and respectable quartiles across various categories, including Q3 positions in key areas as of 2023, the journal offers an invaluable platform for researchers and clinicians aiming to bridge the gap between experimental research and clinical practice. Located in Pavia, Italy, the journal welcomes contributions from scholars worldwide, fostering a collaborative environment that enhances knowledge exchange and encourages innovative approaches in myological research.

Degenerative Neurological and Neuromuscular Disease is a distinguished academic journal published by DOVE MEDICAL PRESS LTD, focusing on the latest advancements in the field of neurology and neuromuscular disorders. With a commitment to disseminating high-quality research, the journal aims to provide a critical platform for researchers, healthcare professionals, and students to share and engage with groundbreaking studies that advance our understanding of degenerative conditions affecting the nervous system. Although the journal's impact factor and h-index are currently not available, its open access model ensures that the valuable findings published within are accessible to a global audience, thereby fostering collaboration and innovation in neurological health. The journal's address is PO BOX 300-008, Albany, Auckland 0752, New Zealand, reflecting its international relevance and commitment to advancing the field of neurology. As the understanding of neurodegenerative diseases and neuromuscular challenges continues to evolve, Degenerative Neurological and Neuromuscular Disease serves as an essential resource for anyone dedicated to improving patient outcomes and advancing scientific knowledge.

The Orphanet Journal of Rare Diseases, published by BMC since 2006, serves as a vital platform for the dissemination of groundbreaking research in the realm of rare diseases. With a notable Q1 ranking in both the Medicine (miscellaneous) and Pharmacology (medical) categories, and a respectable Q2 ranking in Genetics (clinical), the journal is recognized for its impactful contributions, evidenced by its position in the top quartiles of Scopus rankings. This open-access journal allows unrestricted access to its content, promoting a global exchange of knowledge among researchers, healthcare professionals, and academics. By covering a broad spectrum of rare diseases, the Orphanet Journal aims to enhance awareness, improve diagnosis and treatment, and ultimately contribute to the improvement of patients' lives. With a commitment to high-quality research, this journal stands as an essential resource for anyone involved in the study or treatment of rare diseases.

Blood Advances is a premier, peer-reviewed journal published by Elsevier, dedicated to the field of hematology. With an impressive impact factor and classified within the Q1 category of hematology for 2023, it ranks as the 16th out of 137 journals in the Scopus Medicine Hematology category, placing it in the top 88th percentile globally. This influential journal, which has been disseminating invaluable research since its inception in 2017, focuses on advancing knowledge and innovation in blood science, including clinical and laboratory aspects of hematology. Although it offers limited open access features, its comprehensive scope encompasses various topics relevant to both researchers and practitioners. Located in the United States and managed from Amsterdam, Blood Advances provides a vital platform for the dissemination of groundbreaking research, making significant contributions to the understanding and treatment of blood disorders. Researchers, professionals, and students alike will find this journal an essential resource for keeping abreast of the latest developments and advancements in hematology.

DYSPHAGIA, published by Springer, is a premier journal dedicated to advancing the study of swallowing disorders, a critical area within the fields of Gastroenterology, Otorhinolaryngology, and Speech and Hearing. With an ISSN of 0179-051X and E-ISSN 1432-0460, this journal serves as a vital resource for researchers, clinicians, and students alike, providing cutting-edge research and reviews that inform clinical practice and enhance patient care. As a testament to its influence, DYSPHAGIA holds a Q2 ranking in Gastroenterology and Q1 rankings in both Otorhinolaryngology and Speech and Hearing for 2023. Its Scopus rankings further position it among the leading journals in its field, highlighting its importance and impact within the academic community. The journal publishes contributions that encompass a spectrum of topics related to swallowing, making it an essential platform for disseminating knowledge and fostering innovative solutions in the management of dysphagia. Operating from New York, NY, DYSPHAGIA invites contributions that align with its mission to advance the understanding and treatment of swallowing disorders through rigorous scientific inquiry and discourse.

Annals of Dermatology is a prestigious academic journal published by the Korean Dermatological Association, focusing on the latest research and advancements in the field of dermatology. With a commitment to advancing knowledge in skin health and disease, this journal serves as a vital resource for researchers, clinicians, and students working in dermatology and related disciplines. Since its inception in 1989, it has evolved to consolidate its position in the academic community, boasting a Q2 ranking in the 2023 Dermatology category and a Scopus rank of #87 out of 142, placing it in the 39th percentile. Although it operates under a subscription model, the journal's impact factor reflects its significance in advancing dermatological research, attracting innovative studies and reviews that shape clinical practice. With a publication history extending from 1989 to 1996 and then from 2008 to the present, Annals of Dermatology continues to be an essential publication for those devoted to improving skin health.

Therapeutic Advances in Neurological Disorders, published by SAGE Publications Ltd, is a leading open access journal dedicated to the advancement of knowledge in the field of neurology. Since its inception in 2008, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for the dissemination of high-quality research that improves the understanding and treatment of neurological disorders. With a commendable impact factor and ranked Q1 in multiple categories, including Neurology and Pharmacology for 2023, it exemplifies excellence in scholarly contributions. The journal's Scope encompasses a wide array of topics, providing insights that are pivotal for clinical practice and pharmacological development. Additionally, with its commitment to open access since 2017, Therapeutic Advances in Neurological Disorders ensures that its research reaches a global audience, fostering collaboration and innovation in neurological science.